Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Cyber Savings Season: Get 30% off ACS membership with promo code CYBER24. Offer valid though Dec. 11.

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Business

Seqirus opens lab in Massachusetts for sa-mRNA research

by Michael McCoy
February 11, 2022 | A version of this story appeared in Volume 100, Issue 6
Advertisement

Most Popular in Business

Seqirus's new facility in Waltham, Massachusetts.
Credit: Seqirus
Seqirus says its new facility will have the capacity to house 300 full-time employees.

Seqirus, part of the flu vaccine firm CSL, has opened a facility in Waltham, Massachusetts, focused on self-amplifying messenger RNA (sa-mRNA), which Seqirus calls the next generation of mRNA technology. mRNA vaccines give instructions to cells to make a protein, stimulating an immune response. sa-mRNA also instructs the body to replicate the mRNA, amplifying the amount of protein made. Seqirus says the result could be vaccines for the flu and other diseases that are effective at smaller doses and have fewer side effects.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE